NKE — NIKE, Inc.

The price action and recent commentary are clearly bearish: the stock is near its 52-week low of $38.17, below all major moving averages, with persistent headlines about China declines, heavy promotional discounting, and shelf-space losses to Hoka, On, and New Balance. The FMP analyst consensus technically reads as Buy, but the live research tone is more cautious, and subdued forward EPS estimates of $1.73 suggest the sell-side has not yet penciled in a sharp recovery. Insider buying by CEO Elliott Hill is a positive signal but has not been enough to change the tape.

The three-year quarterly data show a clear two-stage story: Nike's revenue ran between $12.4B and $13.4B per quarter in FY24, then fell roughly 10% into the $11.0-$12.4B range by FY25 and has essentially stabilized over the last four quarters (FY26 revenue ~$46.4B vs FY25 ~$46.3B). Operating margins followed the same arc, collapsing from ~12-13% in FY24 to a low of 2.9% in Q4 FY25, then recovering to 7.9-8.1% in Q1/Q2 FY26 and a much stronger 12.0% in Q4 FY26. Net income and EPS show a similar recent inflection: Q4 FY26 EPS of $0.72 versus $0.14 a year earlier. That is a positive one-quarter data point, but the bigger picture is two years of margin compression that may finally be bottoming.

On headline multiples, NKE is cheap versus its own history: 18.3x trailing P/E versus the 5-year average of 27.7x, 1.23x price-to-sales versus the 5-year average of 2.68x, and a 3.55% dividend yield at the bottom of the 52-week range. The catch is that forward EPS is estimated at only $1.73, putting the stock at roughly 22x forward earnings, and the negative PEG is a warning that earnings are still expected to decline before they recover. So this is 'cheap for a business that has gotten worse,' not obviously 'cheap for a stable grower.'

At $38.44, the market is paying 18.3x trailing earnings but about 22x forward estimates, which means it is not pricing in a strong recovery; it is pricing in roughly flat-to-lower earnings. That leaves room for upside if the September 29, 2026 report confirms stabilization and estimates begin moving higher. Conversely, if earnings keep sliding toward the $1.75 area, the stock is not as cheap as the trailing P/E makes it look. The key swing factor is the direction of estimate revisions, not just the low headline multiple.

As of 2026-08-27, RSI(14) stood at 36.6, weak but not yet oversold. Price was 5.8% below the 20-day SMA, 8.5% below the 50-day SMA, and 26.3% below the 200-day SMA, with the 52-week low at $38.17. This is a downtrend, not a confirmed bottoming pattern. For timing, the prudent approach is to wait for either a washout close below the low with RSI under 30 or a sustained reclaim of the 50-day moving average.

• Subdued global consumer spending and a promotional retail environment are pressuring Nike's full-price selling power.
• Greater China is a major drag, with consecutive double-digit sales declines as Anta and Li-Ning take share from Western brands.
• Tariff and IEEPA refund noise around $1 billion is distorting reported gross margins and makes organic trends harder to read.
• Hoka, On, and New Balance have captured wholesale shelf space, forcing Nike to discount and defend distribution.
• High interest rates and cautious discretionary spending are weighing on the entire apparel and footwear sector.

• Q1 FY2027 earnings on September 29, 2026: any sign of North America wholesale recovery or stabilization in Greater China could trigger a re-rating.
• Elliott Hill's turnaround execution, including new product launches like Air Jordan 41 and Pegasus Plus 2, rebuilding wholesale relationships, and improving DTC/digital growth.
• A turn in the estimate revision cycle: if forward EPS of $1.73 stops falling and gets revised upward, the cheap headline multiple starts to compound.

• Greater China keeps deteriorating and domestic competitors continue to gain share.
• Nike's brand heat does not return quickly, and Hoka/On/New Balance keep taking floor space, forcing continued promotional activity.
• Operating margins stay near the current ~8% level, leaving TTM free cash flow of about $2.2B thin relative to the dividend, raising payout-sustainability concerns.
• The wholesale repair fails to deliver meaningful volume because retail partners remain cautious about Nike's direct-to-consumer-first strategy.

At $38.44, NKE offers a strong balance sheet, a historically low valuation, and early signs of margin stabilization, but the business is still mid-turnaround with real competitive and China risks. For a patient investor, the risk/reward is favorable as long as the next quarter or two confirm that revenue and margins are not rolling back over. This is a positive lean on valuation and financial health, not a declaration that the operational problems are solved.

I applied a 17x EV/EBIT multiple to TTM operating income of roughly $3.8B, added net cash of about $1.6B, and divided by approximately 1.48B shares outstanding, yielding roughly $45. The 17x multiple is below Nike's historical average but above the current 14.5x EV/EBIT, reflecting depressed margins and competition risk while still allowing for a successful turnaround.